These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 30032331)
61. Establishment of a novel microscale thermophoresis ligand-binding assay for characterization of SLC solute carriers using oligopeptide transporter PepT1 (SLC15 family) as a model system. Clémençon B; Lüscher BP; Hediger MA J Pharmacol Toxicol Methods; 2018; 92():67-76. PubMed ID: 29580877 [TBL] [Abstract][Full Text] [Related]
62. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367 [TBL] [Abstract][Full Text] [Related]
63. A proteomic approach for the identification of novel lysine methyltransferase substrates. Levy D; Liu CL; Yang Z; Newman AM; Alizadeh AA; Utz PJ; Gozani O Epigenetics Chromatin; 2011 Oct; 4():19. PubMed ID: 22024134 [TBL] [Abstract][Full Text] [Related]
64. Fragment Hotspot Mapping to Identify Selectivity-Determining Regions between Related Proteins. Smilova MD; Curran PR; Radoux CJ; von Delft F; Cole JC; Bradley AR; Marsden BD J Chem Inf Model; 2022 Jan; 62(2):284-294. PubMed ID: 35020376 [TBL] [Abstract][Full Text] [Related]
65. Binding site characterization - similarity, promiscuity, and druggability. Ehrt C; Brinkjost T; Koch O Medchemcomm; 2019 Jul; 10(7):1145-1159. PubMed ID: 31391887 [TBL] [Abstract][Full Text] [Related]
66. Computer-aided pattern scoring (C@PS): a novel cheminformatic workflow to predict ligands with rare modes-of-action. Stefan SM; Stefan K; Namasivayam V J Cheminform; 2024 Sep; 16(1):108. PubMed ID: 39313842 [TBL] [Abstract][Full Text] [Related]
67. NSD1: A Lysine Methyltransferase between Developmental Disorders and Cancer. Tauchmann S; Schwaller J Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575025 [TBL] [Abstract][Full Text] [Related]
68. Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer. Danishuddin ; Kumar V; Parate S; Bahuguna A; Lee G; Kim MO; Lee KW Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358125 [TBL] [Abstract][Full Text] [Related]
69. Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization. Rabal O; Castellar A; Oyarzabal J J Cheminform; 2018 Jul; 10(1):32. PubMed ID: 30032331 [TBL] [Abstract][Full Text] [Related]
70. Orphan receptor ligand discovery by pickpocketing pharmacological neighbors. Ngo T; Ilatovskiy AV; Stewart AG; Coleman JL; McRobb FM; Riek RP; Graham RM; Abagyan R; Kufareva I; Smith NJ Nat Chem Biol; 2017 Feb; 13(2):235-242. PubMed ID: 27992882 [TBL] [Abstract][Full Text] [Related]
71. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase. Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173 [TBL] [Abstract][Full Text] [Related]
72. Recent Advances in Chemical Tools for the Regulation and Study of Protein Lysine Methyltransferases. Hirano T; Mori S; Kagechika H Chem Rec; 2018 Dec; 18(12):1745-1759. PubMed ID: 30079624 [TBL] [Abstract][Full Text] [Related]
73. Specificity analysis of protein lysine methyltransferases using SPOT peptide arrays. Kudithipudi S; Kusevic D; Weirich S; Jeltsch A J Vis Exp; 2014 Nov; (93):e52203. PubMed ID: 25489813 [TBL] [Abstract][Full Text] [Related]
74. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809 [TBL] [Abstract][Full Text] [Related]